Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)

BACKGROUND: Multiple androgens drive prostate cancer progression and higher pre-treatment levels of androgens, even within the castrate range, have been previously shown to be associated with an improved overall survival (OS) in mCRPC. Docetaxel impairs microtubules, has androgen receptor (AR) inhib...

詳細記述

保存先:
書誌詳細
出版年:Prostate Cancer Prostatic Dis
主要な著者: Ryan, Charles J, Dutta, Sandipan, Kelly, William K, Russell, Carly, Small, Eric J., Morris, Michael J., Taplin, Mary-Ellen, Halabi, Susan
フォーマット: Artigo
言語:Inglês
出版事項: 2019
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6825875/
https://ncbi.nlm.nih.gov/pubmed/31053766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41391-019-0152-3
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料